Ursprung des Netzwerks ersten Grades von Hannes Schmeil
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Alnylam Germany GmbH
 Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options.
2
| Subsidiary | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Hannes Schmeil
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Alnylam UK Ltd.
 Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK. | Biotechnology | Director/Board Member Director/Board Member | |
The British United Provident Association Ltd.
 The British United Provident Association Ltd. Life/Health InsuranceFinance The British United Provident Association Ltd. provides healthcare products and services. It offers health, dental and travel insurance, optical and audiology, and care homes. The company was founded on April 3, 1947 and is headquartered in London, the United Kingdom. | Life/Health Insurance | Sales & Marketing | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Medical Specialties | Corporate Officer/Principal | |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Ohmeda Pharmaceuticals | Corporate Officer/Principal | ||
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
| BAXTER INTERNATIONAL INC. | Medical Specialties | Sales & Marketing | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chief Executive Officer |
Statistik
International
| Vereinigte Staaten | 8 |
| Vereinigtes Königreich | 5 |
| Schweden | 2 |
| Deutschland | 2 |
| Irland | 2 |
Sektoral
| Health Technology | 13 |
| Finance | 2 |
| Consumer Services | 2 |
Operativ
| Director/Board Member | 7 |
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 5 |
| Independent Dir/Board Member | 3 |
| Sales & Marketing | 2 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Theresa Heggie | 16 |
| David Ronald Jones | 2 |
- Börse
- Insiders
- Hannes Schmeil
- Unternehmensverbindungen
